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Soluble guanylyl cyclase (sGC) is a receptor for the signal-
ing molecule nitric oxide (NO). Binding of NO to the sGC
heme moiety causes up to 400-fold stimulation of its
activity, leading to increased cGMP levels and cGMP-
dependent protein kinase (PKG) activation. As sGC subu-
nits contain putative phosphorylation sites for PKG, we
tested the hypothesis that sGC activity is regulated by
PKG. In vitro kinase assays revealed that sGC is a PKG sub-
strate. In vivo, a constitutively active form of PKG stimu-
lated incorporation of 32P into sGC. We then proceeded to
map the exact phosphorylation site by generating serine
to alanine mutations of putative PKG sites. Wild-type (wt)
sGC co-expressed with a constitutively active form of PKG
exhibited lower basal and NO-stimulated cGMP accumu-
lation, while the serine to alanine sGC was resistant to the
PKG-induced reduction in activity. In line with these
observations, a phosphomimetic serine to aspartate sGC
mutant showed reduced ability to synthesize cGMP.
Using purified sGC and mutants, we observed that the
phosphomimetic sGC mutant exhibited lower Vmax both
under basal and NO-stimulated conditions and that the
decrease in Km after NO stimulation was less pronounced
than that for the wt. Moreover, the phosphorylation defi-
cient sGC exhibited reduced desensitization to acute NO
exposure and facilitated greater VASP phosphorylation.
We conclude that PKG phosphorylates sGC on serine and
phosphorylation inhibits sGC activity, establishing a neg-
ative feedback loop.
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